Small Intestinal Bacterial Overgrowth in Rosacea: Clinical Effectiveness of Its Eradication

antibiotic-therapybreath-testdermatologygastroenterologygut-skin-axis

Small Intestinal Bacterial Overgrowth in Rosacea: Clinical Effectiveness of Its Eradication

Why this matters for your gut health

Rosacea’s cause has long been unclear, and many treatments (antibiotics) work without a clear explanation why. This study proposed and tested a concrete gut-skin mechanism — small intestinal bacterial overgrowth (SIBO) — offering both a plausible cause and a targeted, non-cosmetic treatment path for a disfiguring, quality-of-life-impacting skin disease.

Summary

Researchers tested 113 rosacea patients and 60 healthy controls for SIBO using breath tests. SIBO was far more common in rosacea patients (46%) than controls (5%). SIBO-positive patients were randomized to rifaximin (antibiotic) or placebo; those treated had dramatic clearing of skin lesions, while placebo patients did not improve until later switched to the antibiotic.

Key findings

SIBO prevalence: 52/113 rosacea patients vs. 3/60 controls (P<.001)
SIBO eradication → skin lesions cleared in 78%, improved in 17.7%
Placebo group: no improvement until switched to rifaximin
Remission maintained in 96% of patients for ≥9 months
Papulopustular rosacea correlated most strongly with SIBO; flushing/erythrosis correlated more with H. pylori

Read the full paper

VIEW PDF

Citation

Parodi A, Paolino S, Greco A, Drago F, Mansi C, Rebora A, Parodi A, Savarino V. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759–764. doi:10.1016/j.cgh.2008.02.054